TREATING drug-resistant tuberculosis (DR-TB) patients in the Philippines might become more expensive as cheaper yet quality-assured generic versions of its cure will be restricted in the domestic market. This concern arose as the expiration of Johnson & Johnson’s (J&J) 20-year primary patent for DR-TB drug bedaquiline became effective last July…
The global plan for COVID-19 vaccine fairness fell short Will next time be different? science.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from science.org Daily Mail and Mail on Sunday newspapers.
The antiviral pills, plentiful in the United States, are scarce overseas. Health groups and the White House want to expand access but face obstacles that evoke the H.I.V. epidemic.